Status:
COMPLETED
Characterizing the Immune Response and Neuronal Damage in COVID-19
Lead Sponsor:
Insel Gruppe AG, University Hospital Bern
Collaborating Sponsors:
University of Bern
Conditions:
SARS-CoV Infection
Covid-19
Eligibility:
All Genders
18+ years
Brief Summary
The Investigators plan to study the innate and adaptive immune response, the inflammatory response, and associated complications such as complement activation and neurological damage in SARS-Cov-2 inf...
Detailed Description
The severity of coronavirus disease 2019 (COVID-19) ranges from asymptomatic infection to severe illness requiring mechanical ventilation. Immunological factors which lead to severe disease in certain...
Eligibility Criteria
Inclusion
- PCR confirmed SARS-Cov-2 infection
Exclusion
- Refusal to participate
- Age \< 18 years
Key Trial Info
Start Date :
March 5 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 30 2021
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT04510012
Start Date
March 5 2020
End Date
January 30 2021
Last Update
January 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bern University Hospital
Bern, Switzerland, 3010